In the absence of a surrogate of protection, this study aimed to identify whether serum IgA and IgG antibody responses and two measures of mucosal immunogenicity (ALS and/or fecal IgA antibody responses to VLA1701 antigens) were associated with reduced disease following challenge. This evidence concerns the gene CD79A and amyotrophic lateral sclerosis.